



COPY OF PAPERS
ORIGINALLY FILED

1636

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Rubin et al.

Serial No: 09/635,370

Filed: August 9, 2000

For: Progenitor Cell, Methods and Uses
Related Thereto

Attorney Docket No. CIBT-P02-060

Art Unit: 1636

Examiner: K. Davis


#1636
Beta
RECEIVED
JUL 08 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

June 26, 2002

Date of Signature
and of Mail Deposit


Elisabeth Dunkle

Commissioner of Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed April 8, 2002, in connection with the above application. Please enter the following amendments:

In the specification:

◇◇ Please replace the second full paragraph on page 9 with:

B
Figure 3A-3G. The duct monolayer expresses multiple progenitor cell markers. Monolayers were stained for both insulin (A) and amylase (B). Panel C is a composite showing that some cells express both insulin and amylase. Two morphologically distinct cell types are present, those that are adherent and flat, and cells that are semi-adherent and round. Arrowheads denote* rounded semi-adherent cells that may coexpress both insulin and amylase. Panels D and E show staining for glucagon and PYY, respectively, and Panel F is a composite showing that one of the glucagon-bright cells also expresses PYY. Panel G shows a composite of nuclear PDX-1 (Cy3) and cytoplasmic insulin (FITC) staining. Arrowheads indicate cells that express PDX-1 but not insulin or vice versa.